Original Source(s)
Related Content
FDA Expands Test for Gastric and Esophageal Cancers
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
-
2 min
FDA expands essential thrombocythemia care
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
-
2 min
10 Growing US Metro Areas to Consider for Private Practice
These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.
September 1, 2026
-
5 min
